Bachem Holding AG (Bachem) develops, manufactures and markets peptides, oligonucleotides and complex organic molecules such as active pharmaceutical ingredients (APIs) and biochemicals for research purposes. The company operates as a contract manufacturing organization (CMO) and offers products and services to the pharmaceutical and biotechnology industries. The company provides end-to-end chemistry, manufacturing, and controls (CMC) services, including process development, analytical method development, regulatory support, and dedicated project management to help advance complex modalities efficiently and compliantly. Its business spans two API models: exclusive single-customer programs for innovative, IP-protected New Chemical Entities (NCEs), and multi-customer generic APIs supported by validated processes and comprehensive regulatory documentation (e.g., DMFs and CEPs) for global filings. The company also supplies high-quality protected amino acid building blocks with strong quality control, documentation packages, and flexible quantities. It develops and produces cosmetic peptides using approaches such as Tag-Assisted Peptide Synthesis (TAPS), including options for greener and CMR-free processes.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Bachem focuses its R&D initiatives on process chemistry and technology optimization, rather than developing proprietary drug candidates. The company operates as a process innovation engine, primarily covering process development to pioneer next-generation synthesis techniques that minimize environmental impact and maximize chemical yields. Bachem is also engaged in specialized R&D initiatives such as peptide-oligonucleotide conjugation to enhance pharmacokinetics and stability of oligonucleotide drugs, and it is a member of the ACS Green Chemistry Institute Pharmaceutical Roundtable, optimizing peptide synthesis to minimize hazardous waste. The R&D unit of Bachem is deeply integrated into production operations, with the combined Research/Development and Production division employing 1,158 Full-Time Equivalents (FTEs), representing 46.1% of the entire global workforce. This unit is responsible for managing the company's R&D activities, focusing on process innovation and supporting the scale-up of peptide and oligonucleotide modalities. In FY2025, the company spent CHF10.2 million on its R&D activities, which as a percentage of revenue stood at 1.5%.